請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27525
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊泮池(Pan-Chyr Yang) | |
dc.contributor.author | Jann-Yuan Wang | en |
dc.contributor.author | 王振源 | zh_TW |
dc.date.accessioned | 2021-06-12T18:08:20Z | - |
dc.date.available | 2009-02-19 | |
dc.date.copyright | 2008-02-19 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-12-12 | |
dc.identifier.citation | 1. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Brit Med J 1948;2:769-82
2. Medical Research Council. The prevention of streptomycin resistance by combined chemotherapy. Brit Med J 1952 3. Pfuetze KH, Pyle MM, Hinshaw HC and Feldman WH. The first clinical trial of streptomycin in human tuberculosis. Am Rev Tuber 1955;71:752-4 4. Anonymous. Isoniazid in pulmonary tuberculosis. Lancet 1952;2:19-21 5. Second report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Isoniazid in the treatment of pulmonary tuberculosis. Brit Med J 1953;71:521-36 6. Seventh report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Various combinations of isoniazid with streptomycin or with PAS in the treatment of pulmonary tuberculosis. Brit Med J 1955:435-45 7. Dumelle FJ, Hopewell PC. The CDC and the American Lung Association/American Thoracic Society: an enduring public/private partnership. Centers for Disease Control and Prevention: a century of notable events in TB control. Vol. 1: TB Notes Newslett, 2000:23-7 8. Mount FW, Ferebee SH. United States Public Health service cooperative investigation of antimicrobial therapy of tuberculosis, V. Report on thirty-two-week observations on combinations of isoniazid, streptomycin, and paraaminosalicylic acid. Am Rev Tuber 1954;70:521-6 9. Anonymous. A report from the British Medical Research Council. Cooperative controlled trial of a standard regimen of streptomycin. PAS and isoniazid and three alternative regimens of chemotherapy in Britain. Tubercle 1973;54:99-129 10. East African / British Medical Research Council. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils. Lancet 1974;2:237-40 11. Fox W, Mitchison DA. Short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1975;111:325-53 12. East African / British Medical Research Council. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study. Am Rev Respir Dis 1981;123:165-70 13. East and Central African / British Medical Research Council. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study. Tubercle 1986;67:5-15 14. Singapore Tuberculosis Service / British Medical Research Council. Clinical trial of 6-month and 4-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle 1981;62:95-102 15. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association. Am Rev Respir Dis 1982;126:460-2 16. Algerian working group / British Medical Research Council. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian working group/British Medical Research Council cooperative study. Am Rev Respir Dis 1984;129:921-8 17. International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis regimens of chemotherapy: recommendations from the committee on treatment. Bull IUATLD 1988;63:60-4 18. World Health Organization. Treatment of tuberculosis: guidelines for national programmes, 2003 19. Anonymous. Treatment of tuberculosis. MMWR Recomm Rep 2003;52:1-77 20. World Health Organization. Global tuberculosis control: surveillance, planning, financing. Geneva, Switzerland: World Health Organization, 2006 21. Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999;44:393-5 22. Bozeman L, Burman W, Metchock B, Welch L and Weiner M. Fluoroquinolone Susceptibility among Mycobacterium tuberculosis Isolates from the United States and Canada. Clin Infect Dis 2005;40:386-91 23. Wang JY, Hsueh PR, Jan IS, et al. Empiric treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with poor prognosis in endemic area. Thorax 2006 24. Yew WW, Chau CH, Wong PC, et al. Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction. Drugs Exp Clin Res 1995;21:79-83 25. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 1998;2:265-71 26. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001;61:9-18 27. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-34 28. Tam CM, Chan SL, Kam KM, Goodall RL and Mitchison DA. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis 2002;6:3-10 29. Moss AR, Hahn JA, Tulsky JP, Daley CL, Small PM and Hopewell PC. Tuberculosis in the homeless. A prospective study. Am J Respir Crit Care Med 2000;162:460-4 30. Sumartojo E. When tuberculosis treatment fails. A social behavioral account of patient adherence. Am Rev Respir Dis 1993;147:1311-20 31. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-84 32. Chaulk CP, Moore-Rice K, Rizzo R and Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. Jama 1995;274:945-51 33. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. Jama 1998;279:943-8 34. Kamolratanakul P, Sawert H, Lertmaharit S, et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg 1999;93:552-7 35. World Health Organization. Group at risk: WHO report on the tuberculosis epidemic. Geneva, Switzerland: World Health Organization, 1996 36. Center for Disease Control. Statistics of communecable diseases and surveillance report in Taiwan area, 2003. Taipei, Taiwan: Center for Disease Control, 2004 37. Davies BH. Infectivity of tuberculosis. Thorax 1980;35:481-2 38. Glassroth J, Robins AG and Snider DE, Jr. Tuberculosis in the 1980s. N Engl J Med 1980;302:1441-50 39. van Soolingen D, de Haas PE, Hermans PW, Groenen PM and van Embden JD. Comparison of various repetitive DNA elements as genetic markers for strain differentiation and epidemiology of Mycobacterium tuberculosis. J Clin Microbiol 1993;31:1987-95 40. Collins DM, Stephens DM. Identification of an insertion sequence, IS1081, in Mycobacterium bovis. FEMS Microbiol Lett 1991;67:11-5 41. Mariani F, Piccolella E, Colizzi V, Rappuoli R and Gross R. Characterization of an IS-like element from Mycobacterium tuberculosis. J Gen Microbiol 1993;139:1767-72 42. Fang Z, Morrison N, Watt B, Doig C and Forbes KJ. IS6110 transposition and evolutionary scenario of the direct repeat locus in a group of closely related Mycobacterium tuberculosis strains. J Bacteriol 1998;180:2102-9 43. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-44 44. Gordon SV, Heym B, Parkhill J, Barrell B and Cole ST. New insertion sequences and a novel repeated sequence in the genome of Mycobacterium tuberculosis H37Rv. Microbiology 1999;145 ( Pt 4):881-92 45. Hermans PW, van Soolingen D and van Embden JD. Characterization of a major polymorphic tandem repeat in Mycobacterium tuberculosis and its potential use in the epidemiology of Mycobacterium kansasii and Mycobacterium gordonae. J Bacteriol 1992;174:4157-65 46. Ross BC, Raios K, Jackson K and Dwyer B. Molecular cloning of a highly repeated DNA element from Mycobacterium tuberculosis and its use as an epidemiological tool. J Clin Microbiol 1992;30:942-6 47. Wiid IJ, Werely C, Beyers N, Donald P and van Helden PD. Oligonucleotide (GTG)5 as a marker for Mycobacterium tuberculosis strain identification. J Clin Microbiol 1994;32:1318-21 48. van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993;31:406-9 49. van Soolingen D, Hermans PW, de Haas PE, Soll DR and van Embden JD. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 1991;29:2578-86 50. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997;35:907-14 51. Goyal M, Young D, Zhang Y, Jenkins PA and Shaw RJ. PCR amplification of variable sequence upstream of katG gene to subdivide strains of Mycobacterium tuberculosis complex. J Clin Microbiol 1994;32:3070-1 52. Frothingham R, Meeker-O'Connell WA. Genetic diversity in the Mycobacterium tuberculosis complex based on variable numbers of tandem DNA repeats. Microbiology 1998;144 ( Pt 5):1189-96 53. Magdalena J, Vache'e A, Supply P and Locht C. Identification of a New DNA Region Specific for Members of Mycobacterium tuberculosis Complex. J Clin Microbiol 1998;36:937-43 54. Stead WW. Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection? Am Rev Respir Dis 1967;95:729-45 55. Fletcher HA. Molecular epidemiology of tuberculosis: recent developments and applications. Curr Opin Pulm Med 2001;7:154-9 56. Canetti G, Sutherland I and Svandova E. Endogenous reactivation and exogenous reinfection: their relative importance with regard to the development of non-primary tuberculosis. Bull Int Union Tuberc 1972;47:116-34 57. Grzybowski S, Styblo K and Dorken E. Tuberculosis in Eskimos. Tubercle 1976;57:S1-58 58. van Soolingen D. Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements. J Intern Med 2001;249:1-26 59. Nardell E, McInnis B, Thomas B and Weidhaas S. Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 1986;315:1570-5 60. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994;330:1703-9 61. Garcia-Garcia M, Palacios-Martinez M, Ponce-de-Leon A, et al. The role of core groups in transmitting Mycobacterium tuberculosis in a high prevalence community in Southern Mexico. Int J Tuberc Lung Dis 2000;4:12-7 62. Garcia-Garcia ML, Small PM, Garcia-Sancho C, et al. Tuberculosis epidemiology and control in Veracruz, Mexico. Int J Epidemiol 1999;28:135-40 63. Lathan M, Mukasa LN, Hooper N, et al. Cross-jurisdictional transmission of Mycobacterium tuberculosis in Maryland and Washington, D C, 1996-2000, linked to the homeless. Emerg Infect Dis 2002;8:1249-51 64. Caminero JA, Pena MJ, Campos-Herrero MI, et al. Epidemiological evidence of the spread of a Mycobacterium tuberculosis strain of the Beijing genotype on Gran Canaria Island. Am J Respir Crit Care Med 2001;164:1165-70 65. Kruuner A, Hoffner SE, Sillastu H, et al. Spread of drug-resistant pulmonary tuberculosis in Estonia. J Clin Microbiol 2001;39:3339-45 66. Magnani J, Mathema B, Berger J, et al. Molecular epidemiology of tuberculosis among eight hospitals in New York City, 1996-1997. Int J Infect Dis 2001;5:126-32 67. Quitugua TN, Seaworth BJ, Weis SE, et al. Transmission of drug-resistant tuberculosis in Texas and Mexico. J Clin Microbiol 2002;40:2716-24 68. Toungoussova OS, Sandven P, Mariandyshev AO, Nizovtseva NI, Bjune G and Caugant DA. Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel Oblast, Russia. J Clin Microbiol 2002;40:1930-7 69. Toungoussova OS, Mariandyshev A, Bjune G, Sandven P and Caugant DA. Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates in the Archangel prison in Russia: predominance of the W-Beijing clone family. Clin Infect Dis 2003;37:665-72 70. Ellis BA, Crawford JT, Braden CR, McNabb SJ, Moore M and Kammerer S. Molecular epidemiology of tuberculosis in a sentinel surveillance population. Emerg Infect Dis 2002;8:1197-209 71. Lambregts-van Weezenbeek CS, Sebek MM, van Gerven PJ, et al. Tuberculosis contact investigation and DNA fingerprint surveillance in The Netherlands: 6 years' experience with nation-wide cluster feedback and cluster monitoring. Int J Tuberc Lung Dis 2003;7:S463-70 72. Chaves F, Dronda F, Alonso-Sanz M and Noriega AR. Evidence of exogenous reinfection and mixed infection with more than one strain of Mycobacterium tuberculosis among Spanish HIV-infected inmates. Aids 1999;13:615-20 73. Yeh RW, Hopewell PC and Daley CL. Simultaneous infection with two strains of Mycobacterium tuberculosis identified by restriction fragment length polymorphism analysis. Int J Tuberc Lung Dis 1999;3:537-9 74. Niemann S, Richter E, Rusch-Gerdes S, Schlaak M and Greinert U. Double infection with a resistant and a multidrug-resistant strain of Mycobacterium tuberculosis. Emerg Infect Dis 2000;6:548-51 75. Braden CR, Morlock GP, Woodley CL, et al. Simultaneous infection with multiple strains of Mycobacterium tuberculosis. Clin Infect Dis 2001;33:e42-7 76. Warren RM, Victor TC, Streicher EM, et al. Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med 2004;169:610-4 77. van Rie A, Warren RM, Beyers N, et al. Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling 'strain W' among noninstitutionalized, human immunodeficiency virus-seronegative patients. J Infect Dis 1999;180:1608-15 78. Warren RM, Streicher EM, Sampson SL, et al. Microevolution of the direct repeat region of Mycobacterium tuberculosis: implications for interpretation of spoligotyping data. J Clin Microbiol 2002;40:4457-65 79. van Rie A, Victor TC, Richardson M, et al. Reinfection and Mixed Infection Cause Changing Mycobacterium tuberculosis Drug-Resistance Patterns. Am J Respir Crit Care Med 2005;172:636-642 80. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999;341:1174-9 81. Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005;171:1430-5 82. Caminero JA, Pena MJ, Campos-Herrero MI, et al. Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. Am J Respir Crit Care Med 2001;163:717-20 83. Garcia de Viedma D, Marin M, Hernangomez S, et al. Tuberculosis recurrences: reinfection plays a role in a population whose clinical/epidemiological characteristics do not favor reinfection. Arch Intern Med 2002;162:1873-9 84. El Sahly HM, Wright JA, Soini H, et al. Recurrent tuberculosis in Houston, Texas: a population-based study. Int J Tuberc Lung Dis 2004;8:333-40 85. Bandera A, Gori A, Catozzi L, et al. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. J Clin Microbiol 2001;39:2213-8 86. de Boer AS, van Soolingen D. Recurrent tuberculosis due to exogenous reinfection. N Engl J Med 2000;342:1050-1 87. Jasmer RM, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med 2004;170:1360-6 88. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 1997;119:183-201 89. Das S, Chan SL, Allen BW, Mitchison DA and Lowrie DB. Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Kong before, during and after short-course chemotherapy. Tubercle and Lung Disease 1993;74:47-51 90. Hawken M, Nunn P, Godfrey-Faussett P, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. The Lancet 1993;342:332-337 91. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993;328:1137-44 92. Godfrey-Faussett P, Githui W, Batchelor B, et al. Recurrence of HIV-related tuberculosis in an endemic area may be due to relapse or reinfection. Tubercle and Lung Disease 1994;75:199-202 93. Das S, Paramasivan CN, Lowrie DB, Prabhakar R and Narayanan PR. IS6110 restriction fragment length polymorphism typing of clinical isolates of Mycobacterium tuberculosis from patients with pulmonary tuberculosis in Madras, South India. Tubercle and Lung Disease 1995;76:550-554 94. Sahadevan R, Narayanan S, Paramasivan CN, Prabhakar R and Narayanan PR. Restriction fragment length polymorphism typing of clinical isolates of Mycobacterium tuberculosis from patients with pulmonary tuberculosis in Madras, India, by use of direct-repeat probe. Journal of Clinical Microbiology 1995;33:3037-3039 95. El-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clinical Infectious Diseases 1998;26:1148-1158 96. Sudre P, Pfyffer GE, Bodmer T, et al. Molecular epidemiology of tuberculosis among HIV-infected persons in Switzerland: a countrywide 9-year cohort study. Swiss HIV Cohort Study. Infection 1999;27:323-30 97. Vernon A, Burman W, Benator D, Khan A and Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. The Lancet 1999;353:1843-1847 98. Johnson JL, Okwera A, Nsubuga P, et al. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. International Journal of Tuberculosis and Lung Disease 2000;4:1032-1040 99. Lourenco MCS, Grinsztejn B, Fandinho-Montes FCO, Da Silva MG, Saad MHF and Fonseca LS. Genotypic patterns of multiple isolates of M. tuberculosis from tuberculous HIV patients. Tropical Medicine and International Health 2000;5:488-494 100. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B and Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. The Lancet 2001;358:1687-1693 101. Fitzpatrick LK, Okwera A, Mugerwa R, Ridzon R, Ehiner J and Onorato I. An investigation of suspected exogenous reinfection in tuberculosis patients in Kampala, Uganda. Int J Tuberc Lung Dis 2002;6:550-2 102. Lan NT, Lien HT, Tung le B, Borgdorff MW, Kremer K and van Soolingen D. Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, Vietnam. Emerg Infect Dis 2003;9:1633-5 103. Wang JY, Lee LN, Lai HC, et al. Prediction of the tuberculosis reinfection proportion from the local incidence. J Infect Dis 2007;196:281-288 104. Miller AC, Sharnprapai S, Suruki R, et al. Impact of genotyping of Mycobacterium tuberculosis on public health practice in Massachusetts. Emerg Infect Dis 2002;8:1285-9 105. Crump JA, Reller LB. Two decades of disseminated tuberculosis at a university medical center: the expanding role of mycobacterial blood culture. Clin Infect Dis 2003;37:1037-43 106. Sahn SA, Neff TA. Miliary tuberculosis. Am J Med 1974;54:495-505 107. Anonymous. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161:1376-95 108. Alvarez SZ. Hepatobiliary tuberculosis. J Gastroenterol Hepatol 1998;13:833-9 109. Yew WW, Lee J. Pathogenesis of cervical tuberculous lymphadenitis: pathways to anatomic localization. Tuber Lung Dis 1995;76:275-6 110. Kaufhold A, Podbielski A, Baumgarten G, Blokpoel M, Top J and Schouls L. Rapid typing of group A streptococci by the use of DNA amplification and non-radioactive allele-specific oligonucleotide probes. FEMS Microbiol Lett 1994;119:19-25 111. Jou R, Chiang CY and Huang WL. Distribution of the Beijing family genotypes of Mycobacterium tuberculosis in Taiwan. J Clin Microbiol 2005;43:95-100 112. Lalvani A, Pathan AA, McShane H, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 2001;163:824-8 113. Wang JY, Lee LN, Chou CS, et al. Performance Assessment of a Nested-PCR Assay (the RAPID BAP-MTB) and the BD ProbeTec ET System for Detection of Mycobacterium tuberculosis in Clinical Specimens. J Clin Microbiol 2004;42:4599-603 114. Wang JY, Lee LN and Hsueh PR. Factors changing the manifestation of pulmonary tuberculosis. Int J Tuberc Lung Dis 2005;9:777-783 115. Supply P, Mazars E, Lesjean S, Vincent V, Gicquel B and Locht C. Variable human minisatellite-like regions in the Mycobacterium tuberculosis genome. Mol Microbiol 2000;36:762-71 116. Mazars E, Lesjean EM, Banuls AL, et al. High-resolution minisatellite-based typing as a portable approach to global analysis of Mycobacterium tuberculosis molecular epidemiology. PNAS 2001;98:1901-6 117. Cowan LS, Mosher L, Diem L, Massey JP and Crawford JT. Variable-number tandem repeat typing of Mycobacterium tuberculosis isolates with low copy numbers of IS6110 by using mycobacterial interspersed repetitive units. J Clin Microbiol 2002;40:1592-602 118. van Soolingen D, Borgdorff MW, de Haas PE, et al. Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. J Infect Dis 1999;180:726-36 119. Geng E, Kreiswirth B, Driver C, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 2002;346:1453-8 120. Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994;330:1710-6 121. Bishai WR, Graham NM, Harrington S, et al. Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. Jama 1998;280:1679-84 122. Jasmer RM, Hahn JA, Small PM, et al. A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. Ann Intern Med 1999;130:971-8 123. Kimerling ME, Benjamin WH, Lok KH, Curtis G and Dunlap NE. Restriction fragment length polymorphism screening of Mycobacterium tuberculosis isolates: population surveillance for targeting disease transmission in a community. Int J Tuberc Lung Dis 1998;2:655-62 124. Anh DD, Borgdorff MW, Van LN, et al. Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. Emerg Infect Dis 2000;6:302-5 125. van Soolingen D, Qian L, de Haas PE, et al. Predominance of a single genotype of Mycobacterium tuberculosis in countries of east Asia. J Clin Microbiol 1995;33:3234-8 126. Le TK, Bach KH, Ho ML, et al. Molecular fingerprinting of Mycobacterium tuberculosis strains isolated in Vietnam using IS6110 as probe. Tuber Lung Dis 2000;80:75-83 127. Braden CR, Templeton GL, Cave MD, et al. Interpretation of restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates from a state with a large rural population. J Infect Dis 1997;175:1446-52 128. Sebek M. DNA fingerprinting and contact investigation. Int J Tuberc Lung Dis 2000;4:S45-8 129. Casper C, Singh SP, Rave S, et al. The transcontinental transmission of tuberculosis: A molecular epidemiological assessment. Am J Public Health 1996;86:551-3 130. Glynn JR, Bauer J, de Boer AS, et al. Interpreting DNA fingerprint clusters of Mycobacterium tuberculosis. European Concerted Action on Molecular Epidemiology and Control of Tuberculosis. Int J Tuberc Lung Dis 1999;3:1055-60 131. Glynn JR, Whiteley J, Bifani PJ, Kremer K and van Soolingen D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis 2002;8:843-9 132. Brudey K, Driscoll JR, Rigouts L, et al. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol 2006;6:23 133. Bifani PJ, Mathema B, Kurepina NE and Kreiswirth BN. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol 2002;10:45-52 134. Tsolaki AG, Gagneux S, Pym AS, et al. Genomic deletions classify the Beijing/W strains as a distinct genetic lineage of Mycobacterium tuberculosis. J Clin Microbiol 2005;43:3185-91 135. Hermans PW, Messadi F, Guebrexabher H, et al. Analysis of the population structure of Mycobacterium tuberculosis in Ethiopia, Tunisia, and The Netherlands: usefulness of DNA typing for global tuberculosis epidemiology. J Infect Dis 1995;171:1504-13 136. van Crevel R, Nelwan RH, de Lenne W, et al. Mycobacterium tuberculosis Beijing genotype strains associated with febrile response to treatment. Emerg Infect Dis 2001;7:880-3 137. Manca C, Tsenova L, Bergtold A, et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta. Proc Natl Acad Sci U S A 2001;98:5752-7 138. Lopez B, Aguilar D, Orozco H, et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol 2003;133:30-7 139. Rios-Barrera VA, Campos-Pena V, Aguilar-Leon D, et al. Macrophage and T lymphocyte apoptosis during experimental pulmonary tuberculosis: their relationship to mycobacterial virulence. Eur J Immunol 2006;36:345-53 140. Spira A, Carroll JD, Liu G, et al. Apoptosis genes in human alveolar macrophages infected with virulent or attenuated Mycobacterium tuberculosis: a pivotal role for tumor necrosis factor. Am J Respir Cell Mol Biol 2003;29:545-51 141. Niemann S, Rusch-Gerdes S and Richter E. IS6110 fingerprinting of drug-resistant Mycobacterium tuberculosis strains isolated in Germany during 1995. J Clin Microbiol 1997;35:3015-20 142. Diaz R, Kremer K, de Haas PE, et al. Molecular epidemiology of tuberculosis in Cuba outside of Havana, July 1994-June 1995: utility of spoligotyping versus IS6110 restriction fragment length polymorphism. Int J Tuberc Lung Dis 1998;2:743-50 143. Marttila HJ, Soini H, Eerola E, et al. A Ser315Thr substitution in KatG is predominant in genetically heterogeneous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St. Petersburg area in Russia. Antimicrob Agents Chemother 1998;42:2443-5 144. Bifani PJ, Plikaytis BB, Kapur V, et al. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. Jama 1996;275:452-7 145. Bifani PJ, Mathema B, Liu Z, et al. Identification of a W variant outbreak of Mycobacterium tuberculosis via population-based molecular epidemiology. Jama 1999;282:2321-7 146. Agerton TB, Valway SE, Blinkhorn RJ, et al. Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States. Clin Infect Dis 1999;29:85-92; discussion 93-5 147. Coronado VG, Beck-Sague CM, Hutton MD, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. J Infect Dis 1993;168:1052-5 148. Friedman CR, Stoeckle MY, Kreiswirth BN, et al. Transmission of multidrug-resistant tuberculosis in a large urban setting. Am J Respir Crit Care Med 1995;152:355-9 149. Kurepina NE, Sreevatsan S, Plikaytis BB, et al. Characterization of the phylogenetic distribution and chromosomal insertion sites of five IS6110 elements in Mycobacterium tuberculosis: non-random integration in the dnaA-dnaN region. Tuber Lung Dis 1998;79:31-42 150. Plikaytis BB, Marden JL, Crawford JT, Woodley CL, Butler WR and Shinnick TM. Multiplex PCR assay specific for the multidrug-resistant strain W of Mycobacterium tuberculosis. J Clin Microbiol 1994;32:1542-6 151. Wang JY, Hsueh PR, Wang SK, et al. Disseminated tuberculosis: a 10-year experience in a medical center. Medicine (Baltimore) 2007;86:39-46 152. Mantoux MC. La voie intradermique en tuberculinothe'rapie. Presse Med 1912;20:146-8 153. World Health Organization. The WHO standard tuberculin test. Geneva, Switzerland: World Health Organization, 1963 154. Bearman JE, Kleinman H, Glyer VV and Lacroix OM. A Study of Variability in Tuberculin Test Reading. Am Rev Respir Dis 1964;90:913-9 155. Perez-Stable EJ, Slutkin G. A demonstration of lack of variability among six tuberculin skin test readers. Am J Public Health 1985;75:1341-3 156. Erdtmann FJ, Dixon KE and Llewellyn CH. Skin testing for tuberculosis. Antigen and observer variability. Jama 1974;228:479-81 157. Pouchot J, Grasland A, Collet C, Coste J, Esdaile JM and Vinceneux P. Reliability of tuberculin skin test measurement. Ann Intern Med 1997;126:210-4 158. Furcolow ML, Watson KA, Charron T and Lowe J. A comparison of the tine and Mono-Vacc tests with the intradermal tuberculin test. Am Rev Respir Dis 1967;96:1009-27 159. Chaparas SD, Vandiviere HM, Melvin I, Koch G and Becker C. Tuberculin test. Variability with the Mantoux procedure. Am Rev Respir Dis 1985;132:175-7 160. Menzies D, Pai M and Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-54 161. Andersen P, Munk ME, Pollock JM and Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000;356:1099-104 162. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B and Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005;54:49-55 163. Royal College of Physicians. Tuberculosis: national clinical guidelines for diagnosis, management, prevention, and control. London: Royal College of Physicians, 2006 164. Comstock GW, Edwards LB and Livesay VT. Tuberculosis morbidity in the U.S. Navy: its distribution and decline. Am Rev Respir Dis 1974;110:572-80 165. Comstock GW, Livesay VT and Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974;99:131-8 166. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970;26:28-106 167. Anonymous. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982;60:555-64 168. Nolan CM, Elarth AM. Tuberculos | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27525 | - |
dc.description.abstract | 結核病(tuberculosis)是一個古老的傳染病,但仍是目前世界上死亡人數最高的一種傳染疾病。台灣地區,近年來結核病的發生率仍居高不下,民國九十三年和民國九十四年,連續兩年發生率皆突破每十萬人口 70 人。傳染病防治上的明顯失敗,意味著必須重新檢討結核病的傳播途徑和發病原因,重新規劃有效的防疫措施,以杜絕結核病的發生。以往認為結核病發病的原因是因為原本蟄伏在體內的結核菌再活化而導致疾病,並非再感染到新的結核菌株。但近年來的研究發現,在結核病患者當中,大部分是屬於群聚感染,而且,與一般的傳染病一樣,某些特殊的環境、或特定的帶原者不斷地散播,造成結核病的疫情,可能是結核病之所以無法被撲滅的主因。
結核病的發病機轉,究竟是因為內在的潛伏性結核菌再度活化,或者是外來的結核菌再度感染,是一個十分重要的議題,因為這將會嚴重影響公共衛生政策的制定。撲滅結核病最好的方法,當然是兩方面都可以顧及,但因為公共衛生以及醫療資源是有限的,實際上兩者無法兼顧。所以如果是再活化這一個機轉比較重要,那麼就應該要將更多的資源投注在發病個案的掌握及治療;相反的,如果是再感染這一個機轉比較重要,那麼除了發病個案的管理治療以外,就必須要將一部份的資源用在新個案的尋找上面。這樣,才能夠用有限的資源,達到最大的成效。 直到西元 2005 年的六月,一共有 23 篇文章探討再感染和再活化這個議題。將這些研究結果歸類後可以發現,在發生率小於每年每十萬人口中五十人的地區,再感染比率平均為 18.3%;但如果是在結核病發生率介於五十人到三百人的地區,再感染比率介於 20% 到 36% 之間;而在發生率超過三百人的地區,再感染的比率會高達七成以上。這暗示著結核病的發生率愈高,再感染比率也就愈高。因此我們假設,在台灣這個結核病的盛行地區,再感染這一個途徑,在病因學上扮演著相當重要的角色。我們將分四個部份進行研究設計與分析。 在研究的第一個部份,針對整體一般結核病個案和散播性結核病患者的菌株進行基因型鑑定,分析群聚感染所佔的比率,推測近期傳染的重要性。在1999 年到 2005 年隨機挑選的 250 株菌株中,有 205 株成功得做完基因型鑑定。總共有 66 個基因型,其中 156(76.1%)個患者屬於群聚感染。此外,由 1995 年到 2004 年這十年當中,64 位散播性結核病患者的菌株中,鑑定結果顯示總共有 22 種基因型,47(73%)個患者屬於群聚感染。 在研究的第二個部份,我們將針對不同的族群,利用結核菌特有抗原與血液中 T 細胞共同培養後,偵測 γ 型干擾素的產量。藉由分析不同族群中結核菌的感染率,希望可以證實的確有接觸後感染或再感染的情況發生。總共有 13 個醫護人員、43 位結核病患的同住家屬、以及 49 位培養確定為結核病之患者接受免疫檢測,結果有 1(8%)位醫護人員、24(56%)位家屬、和43(88%)位結核病患有陽性反應。 在研究的第三個部份,針對臨床分離的結核菌株、抗酸性塗片陽性的痰液檢體,偵測是否同時存在有北京家族或非北京家族的結核菌株,以了解多重感染的比率。由 1999 年到 2004 年這六年的 100 株菌株中,有 17(17%)株在解凍後無法培養出結核菌。剩下的 83 株當中,14(17%)株為多重感染。另外,在 2007 年 10 月 1 日到 15 日,13 個結核菌聚合酶連鎖反應陽性的抗酸性塗片陽性痰液檢體中,2(15%)個是多重感染。 在研究的第四個部份,由臺大醫院培養確定為結核病的個案中,挑出完治後復發的個案,收集前後兩次發病的結核菌株行基因型比對,結果顯示,在 1999 年到 2004 年這六年中一共有 2071 位培養確定為結核病的患者,共有 61 位完治後復發(2.9%),其中有 49 位兩次發病的結核菌株均有保存下來。基因型比對後發現 25(51%)位患者是因為再感染所引起的復發。 第一部份的研究結果與之前針對台灣各地結核菌株的分子流行病學研究結果相同,超過七成屬於群聚感染,這表示台灣地區的結核病患中,近期傳染而造成發病的比率很高,也就意味著再感染這一個致病機轉可能是相當重要的。 第二部份的研究結果顯示,結核病患者的家屬在密切接觸病患之後,受到結核菌再次感染的比率很高,這一點,也間接證實了近期暴露之後所造成的再感染,可能比以往被感染的比率還高。 由於北京家族的結核菌株佔台灣整個結核菌族群的一半左右,因此,若不考慮菌株之間的不同,多重感染的情況中,應該有一半會是混合著一株北京家族結核菌株和一株非北京家族結核菌株的組合。由第三部份的研究結果可以知道,臺大醫院結核病患者當中,多重感染的比率大約在 15% 至 17% 左右。根據這樣的發現,我們可以推論,台灣地區可能有超過三成的結核病患者是多重感染。而多重感染,廣義來說,其實也算是一種再感染,因此,再感染確實在台灣地區結核病的發病機轉上,佔有很重要的角色。 我們第四部份的研究顯示,在整整六年的期間,所有培養確定為結核病的患者,有 2.9% 的個案復發,其中超過一半是因為再感染所引起。這樣的結果表示治療過後的結核病患,每年結核病的發生率是 0.25% 左右,比一般民眾得到結核病機率大了四倍左右。這個發現表示曾經得過結核病的患者,更容易再次得到結核病,再感染的機會也比一般人高。 根據最新的結核病治療標準指引,對於一般病患,標準的治療是合併四種藥物;但如果患者之前已經有過結核病或曾經接受治療,一開始的治療會建議併用五種藥物。如果復發個案可以提早知道是再感染而發病,那麼和一般結核病患者一樣,僅只使用四種藥物,而不需額外再加一種。但如果知道是因為再活化而造成復發,一開始使用五種藥物治療就有其必要性。我們的結果顯示,在各種臨床的徵象上,包括年齡、性別、系統性疾病、臨床症狀及其時間、以及胸部 X 光的表現,再感染的患者與再活化的患者並沒有顯著的不同,這也就代表著,臨床醫師根本無法根據患者的臨床表現猜測究竟是再活化還是再感染。因此,在結核病發生率較高的地區,既然再感染所佔的比率可能大過一半以上,利用分子生物學的方法快速得知結核菌株的抗藥性,以決定治療的處方,將是十分重要的課題。 既然再感染在台灣地區以及其他結核病盛行地區很重要,那麼主動、積極、和即時地篩檢,找出病患將是十分重要的防疫措施。目前世界衛生組織以及各國結核病醫學會並不推薦大規模的結核病篩檢以降低結核病的發生率,但對於某些結核病的高危險群,像是住院病患、門診長期追蹤病患、囚犯、無家可歸的人、以及藥物濫用者等等,規則篩檢究竟有沒有實際上的幫助,目前仍然有爭議。其實,在這幾個特殊的環境中,由於人與人之間的接觸相當頻繁,加上宿主的抵抗力也較差,因此,也正是再感染比率很高的地方。而我們已經知道,結核病發生率高的國家,再感染的比率也隨著增高,因此,大規模篩檢的可行性和防疫上的成本效益,事實上還是需要再次確認,但究竟要挑出哪些高危險族群進行篩檢、用什麼方法做篩檢、以及多久篩檢一次,仍需要更多的研究才可以確定。 總而言之,我們的研究,分四個部份,利用結核菌株的群聚、多重感染分析、和結核病暴露者的免疫反應、以及復發患者的菌株基因型比對等方法,證實在台灣地區,的確有再感染的現象存在,而且比再活化來得更重要,未來台灣地區公共衛生政策的擬定上,除了加強落實短程直接觀察治療法以外,規則的篩檢以積極發掘結核病個案也是不容忽視的方案。期待我們的努力與大家的投入,可以讓未來的台灣,不再是一個結核病的盛行地區。 | zh_TW |
dc.description.abstract | Tuberculosis (TB) is an infectious disease causing enormous morbidities and mortality for thousands of years. In Taiwan, the incidence of TB was still higher than 70 per 100,000 people in 2004 and 2005. The failure in controlling TB implies that we should re-evaluate the routes of transmission and the mechanisms for the development of TB, and re-design the policies for public health and disease control. It was believed previously that all cases of active TB were resulted from reactivation of dormant bacilli, rather than reinfection of a new TB strain. However, many recent studies revealed that a significant proportion of TB patients belonged to clusters. The results of some studies even suggested that recent transmission could be more important than reactivation in the development of active TB. It is a very important issue whether reactivation or reinfection is responsible for the development of most active TB because it changes the policy in public health. If reinfection is more important, besides case holding, more resources should be distributed on finding source cases (cases finding).
Up to June 2005, a total of 23 studies reporting the relative contributions of reinfection and reactivation in patients with TB relapse were identified. The results of the studies performed in areas with the annual incidence being less than 50 cases per 100,000 people showed that the reinfection proportion was 18.3% in average. When the annual incidence was between 50 and 300 cases per 100,000 people, the reinfection proportion ranged from 20% to 36%. Moreover, in area where the annual incidence was higher than 300 cases per 100,000 people, more than 70% of patients with TB relapse were due to reinfection. These imply that the higher the local incidence of TB, the more important reinfection is. Based on those evidences, we hypothesize that in Taiwan, an endemic area of TB, reinfection should have a major contribution in the development of active TB. In the first part of our study, we genotyped the clinical isolates of M. tuberculosis from patients with TB or disseminated TB in National Taiwan University Hospital. The proportion of patients with recent transmission was estimated by cluster analysis. From 1999 to 2005, 250 isolates were randomly selected for genotyping. The results were available in 205, belonging to 66 genotypes. Among them, 156 (76.1%) were clusters. In addition, genotyping for 64 isolates from patients with disseminated showed that there was 22 genotypes and 47 (73%) isolates were clusters. Compatible with previous molecular epidemiologic study in Taiwan, our results showed that more than 70% of clinical M. tuberculosis isolates were clustered. These findings and our data suggests that recent transmission has a major contribution in the development of active TB in Taiwan. In the second part, we included health care workers, culture-confirmed TB patients, and family contacts for ex-vivo immune study, which detecting the production of interferon-γ from T cells after co-culture with M. tuberculosis-specific antigens. A total of 13 health care workers, 49 culture-confirmed TB patients, and 43 family contacts received immune study. The result was positive in 1 (8%), 43 (88%), and 24 (56%), respectively. The results demonstrated that people can be reinfected after contact to patients with active TB. This finding further emphasizes the importance of reinfection in the development of active TB in Taiwan. In the third part of our study, the proportion of multiple infection in all TB patients was evaluated by detecting the presence of Beijing strain and non-Beijing strain in clinical isolates of M. tuberculosis and acid-fast smear-positive respiratory specimens from TB patients in NTUH. First, 100 clinical isolates from 1999 to 2004 were randomly selected. Among the 83 isolates with results available, 14 (17%) were multiply infected. Furthermore, among 13 TB-PCR-positive and smear-positive respiratory specimens collected during Oct. 1, 2007 and Oct. 15, 2007, 2 (15%) were multiply infected. Because the about half of the clinical M. tuberculosis isolates in Taiwan were Beijing strain, we could roughly estimate that about half of the patients with multiple infection are simultaneously infected by one Beijing strain and one non-Beijing strain. Our results suggested that multiple infection is a common situation in Taiwan, probably occurring in 30% of the TB patients. Compatible with the other results of our studies, this finding demonstrates that reinfection plays an important role in the tuberculosis in Taiwan. In the final part of our study, culture-confirm TB patients who experienced relapse after complete treatment in NTUH were identified. The reinfection proportion was calculated by genotyping the clinical isolates from both episodes of these patients. From 1999 to 2004, a total of 2071 culture-confirmed TB patients were identified. Among them, 61 (2.9%) experienced relapse after complete treatment. The clinical isolates of both episodes were preserved in 49 patients. The results of genotype comparing showed that 25 (51%) were reinfection. The final part of our study revealed that 2.9% of the culture-confirmed TB patients relapsed within the 6-year study period; half of them being reinfection. Therefore, the incidence of TB among cured patients was 0.25%, which was 4-fold higher than in the general population. The finding implies that cured patients have a higher risk on disease due to reinfection. According to the guideline for the treatment of TB, the standard regimen for general TB is four-combined regimen. However, if resistant TB is suspected, using five-combined regimen until the results of susceptibility test are available is recommended. Therefore, if we can early diagnosis reinfection in patients with TB relapse, four, rather five, drugs are enough for treatment. On the other hand, using five-combined regimen is necessary in patients with reactivation after complete treatment. However, our results suggest that clinical characteristics, including age, sex, underlying co-morbid conditions, symptoms and their duration, and the findings of chest radiographs, fail to differentiate between reinfection and reactivation. Therefore, in endemic areas where the reinfection probably accounts for more than 50% of all TB cases, rapid detection of drug resistance by molecular biologic methods to determine treatment regimen is an important issue. Since reinfection plays an important role in the development of active TB in Taiwan, aggressive and active surveillance to detect source cases would be important in disease control. At present, mass screening is not recommended by the World Health Organization. However, in certain high-risk groups, such as hospitalized patients, those with underlying co-morbid conditions, prisoners, drug abusers, and the homeless, whether routine screening is cost-effective or not remains undetermined. In addition, since reinfection is common in endemic areas of TB, routine screening for the high-risk patients may be even more feasible in those areas. In conclusion, by detecting the proportion of clusters and multiple infection in clinical isolates of M. tuberculosis, the presence of immune response in TB contacts, and comparing the genotypes of the clinical isolates in both episodes in patients with TB relapse after complete treatment, we had proven that reinfection not only existed but had a major contribution to the development of active TB in Taiwan. Therefore, the policy of public health and TB control should emphasize both case holding and case finding. With the understanding of the epidemiology of TB, we hope Taiwan will not be an endemic area of TB in the near future. | en |
dc.description.provenance | Made available in DSpace on 2021-06-12T18:08:20Z (GMT). No. of bitstreams: 1 ntu-96-D91421009-1.pdf: 3205986 bytes, checksum: 5567050bc7aaf2e50caecac78e1beb7b (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 口試委員會審定書 ----------------------------------- 1
序言 ----------------------------------------------- 2 中文摘要 ------------------------------------------- 3 英文摘要 ------------------------------------------- 6 目錄 ----------------------------------------------- 9 圖目錄 --------------------------------------------- 10 表目錄 --------------------------------------------- 11 壹、緒論 ------------------------------------------- 12 一、研究動機及背景 --------------------------------- 12 二、研究問題及重要性 ------------------------------- 29 三、研究的假說與特定目的 --------------------------- 36 貳、研究的方法與材料 ------------------------------- 38 一、群聚感染的分析 --------------------------------- 38 二、各族群中結核菌的感染分析 ----------------------- 40 三、結核菌多重感染的分析 --------------------------- 42 四、結核病完治後培養確定復發個案菌株基因型的分析比對 46 叁、結果 ------------------------------------------- 49 第一部份 ------------------------------------------- 49 第二部份 ------------------------------------------- 50 第三部份 ------------------------------------------- 51 第四部份 ------------------------------------------- 53 肆、討論 ------------------------------------------- 55 伍、展望 ------------------------------------------- 81 陸、論文英文簡述 ----------------------------------- 94 柒、參考文獻 --------------------------------------- 107 捌、圖表 ------------------------------------------- 138 玖、附錄:相關論文發表 ----------------------------- 174 | |
dc.language.iso | zh-TW | |
dc.title | 再感染對台灣地區結核病發展的重要性 | zh_TW |
dc.title | The importance of reinfection in the development of tuberculosis in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-1 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 薛博仁(Po-Ren Hsueh) | |
dc.contributor.oralexamcommittee | 楊偉勛(Wei-Shiung Yang),賴信志(Hsin-Chih Lai),張峰義(Feng-Yee Chang),蘇維鈞(Wei-Juin Su) | |
dc.subject.keyword | 結核病,再感染,再活化,多重感染,群聚感染,復發,免疫檢測, | zh_TW |
dc.subject.keyword | tuberculosis,reinfection,reactivation,multiple infection,relapse,immunoassay, | en |
dc.relation.page | 177 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-12-13 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 3.13 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。